Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28.5M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
1.67M
-
Shares change
-
+575K
-
Total reported value, excl. options
-
$7.69M
-
Value change
-
+$2.64M
-
Number of buys
-
34
-
Number of sells
-
-1
-
Price
-
$4.61
Significant Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q1 2016
36 filings reported holding OCX - Oncocyte Corporation - Common Shares, No Par Value as of Q1 2016.
Oncocyte Corporation - Common Shares, No Par Value (OCX) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.67M shares
of 28.5M outstanding shares and own 5.86% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (1.09M shares), VANGUARD GROUP INC (95.1K shares), BlackRock Institutional Trust Company, N.A. (92.9K shares), BlackRock Fund Advisors (72.7K shares), Artal Group S.A. (64.1K shares), Manatuck Hill Partners, LLC (61.8K shares), STATE STREET CORP (36.1K shares), NORTHERN TRUST CORP (29.3K shares), GOLDMAN SACHS GROUP INC (29.2K shares), and GEODE CAPITAL MANAGEMENT, LLC (17.7K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.